期刊文献+

老年心房颤动并发脑梗死127例分析及抗凝治疗 被引量:2

下载PDF
导出
摘要 目的分析老年心房颤动(房颤)并发脑梗死患者的临床特征及抗凝治疗现状。方法选取2012-07—2015-07在我院住院确诊的179例老年房颤并发脑梗死患者为研究对象,根据既往是否有房颤病史,分为既往有房颤组和既往无房颤组,对所收集的临床资料进行统计学分析。结果 (1)2组患者既往有房颤组的风心病、甲状腺功能异常、既往脑梗死的比例高于既往无房颤组,差异有统计学意义(P<0.05);余临床基线资料差异均无统计学意义(P>0.05);(2)2组单独应用华法林、阿司匹林、氯吡格雷上比较,差异均无统计学意义(P>0.05);既往有房颤组应用阿司匹林联合氯吡格雷的比例高于既往无房颤组,差异具有统计学意义(P<0.05);2组INR值达标率均较低,差异均无统计学意义(P>0.05)。结论老年房颤并发脑梗死的抗凝治疗率及INR值达标率均较低,对出血的担忧和监测INR值的不便影响了抗凝药物的应用。
出处 《中国实用神经疾病杂志》 2016年第13期75-76,77,共3页 Chinese Journal of Practical Nervous Diseases
  • 相关文献

参考文献5

  • 1Cao Feng,Huang Congxin,Jiang Hong,Li Xia,Bao Mingwei,Tang Yanhong.The influence of carvedilol on atrial connexin 40 after myocardial infarction. Acta Cardiologica . 2008
  • 2Eric N. Prystowsky,Jr Benson,Valentin Fuster,Robert G. Hart,G. Neal Kay,Robert J. Myerburg,Gerald V. Naccarelli,D. George Wyse.??Management of Patients With Atrial Fibrillation: A Statement for Healthcare Professionals From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association(J)Circulation . 1996 (6)
  • 3孙艺红,胡大一.华法林对中国人心房颤动患者抗栓的安全性和有效性研究[J].中华内科杂志,2004,43(4):258-260. 被引量:170
  • 4乔秋博,毕齐.老年心房颤动患者合并脑血管病危险因素研究[J].中华老年心脑血管病杂志,2013,15(9):909-911. 被引量:28
  • 5Andrew D. Krahn,Jure Manfreda,Robert B. Tate,Francis A.L. Mathewson,T. Edward Cuddy.??The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the manitoba follow-up study(J)The American Journal of Medicine . 1995 (5)

二级参考文献19

  • 1李焰生.中国后循环缺血的专家共识[J].中华内科杂志,2006,45(9):786-787. 被引量:1131
  • 2Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the
  • 3Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 2001,119(1 Suppl):8S-21S.
  • 4Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest, 2001,119(1 Suppl):108S-121S.
  • 5The stroke prevention in atrial fibrillation investigation. Bleeding during antithrombotic thearapy in patients with atrial fibrillation. Arch Intern Med, 1996, 156:409-416.
  • 6Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med, 1996,124:970-979.
  • 7Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med,1994,120:897-902.
  • 8Stroke prevention in atrial fibrillation investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation Ⅲ randomized clinic trial. Lan
  • 9Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of reccurrent venous thromboembolism. N Engl J Med, 2003,348:1425-1434.
  • 10Hong KS. I)isability adjusted li/e years analysis: implications for stroke research. J Clin Neurol,2011,7 109-114. l.

共引文献199

同被引文献28

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部